DAP Stock Chart & Stats
€184.95
€1.45(0.86%)
At close: 4:00 PM EDT
€184.95
€1.45(0.86%)
Day’s Range― - ―
52-Week Range€138.20 - €208.30
Previous CloseN/A
Volume424.00
Average Volume (3M)581.00
Market Cap
€138.83B
Enterprise Value€162.35K
Total Cash (Recent Filing)€4.35B
Total Debt (Recent Filing)€26.56B
Price to Earnings (P/E)40.3
Beta0.65
Next Earnings
Oct 21, 2026EPS Estimate
1.68Next Dividend Ex-DateN/A
Dividend Yield0.63%
Share Statistics
EPS (TTM)5.65
Shares Outstanding702,986,100
10 Day Avg. Volume565
30 Day Avg. Volume581
Financial Highlights & Ratios
PEG Ratio-9.26
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€195.88Price Target Upside5.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)7.48
Revenue Forecast (FY)€23.16B
Bulls Say, Bears Say
Bulls Say
Strong Free-cash-flow GenerationDanaher’s substantial and consistent free cash flow provides internal funding for research, acquisitions, capital investment, and shareholder returns. Healthy conversion from earnings also supports resilience through demand cycles and strengthens the company’s ability to sustain its long-term operating model.
Recurring Consumables And Installed-base EconomicsDanaher benefits from an installed base that drives repeat purchases of consumables, reagents, maintenance, and support services. This mix creates customer switching friction and makes revenue more durable than a model dependent only on episodic instrument sales or laboratory capital spending.
Improving Core Demand And Accretive Portfolio ExpansionUnderlying demand is improving outside respiratory, while the Masimo and StatLab transactions expand Danaher’s portfolio with businesses described as accretive and highly recurring. Successful integration could broaden customer reach, reinforce diagnostics exposure, and support multi-year growth.
Bears Say
Modest Growth And Normalized ProfitabilityDanaher remains profitable, but modest recent revenue growth and lower margins and returns than in 2021–2022 indicate that prior-cycle earnings intensity has not fully returned. This limits operating leverage and makes sustained improvement dependent on renewed demand and execution.
Bioprocessing Timing And Shipment UncertaintyDelayed chromatography resin shipments and uncertain customer production schedules can make bioprocessing revenue uneven across quarters. Even if orders remain healthy, repeated timing shifts could defer growth, complicate planning, and reduce near-term utilization of the segment’s commercial capacity.
Academic And Government Market WeaknessBelow-normal academic and government demand remains a persistent drag on selected end markets, particularly where research budgets influence instrument and consumable purchases. Although academia is less than 5% of revenue, prolonged funding weakness can delay customer spending and slow recovery in exposed businesses.
Danaher News
DAP FAQ
What was Danaher Corp.’s price range in the past 12 months?
Danaher Corp. lowest stock price was €138.20 and its highest was €208.30 in the past 12 months.
What is Danaher Corp.’s market cap?
Danaher Corp.’s market cap is €138.83B.
When is Danaher Corp.’s upcoming earnings report date?
Danaher Corp.’s upcoming earnings report date is Oct 21, 2026 which is in 21 days.
How were Danaher Corp.’s earnings last quarter?
Danaher Corp. released its earnings results on Jul 21, 2026. The company reported €1.707 earnings per share for the quarter, beating the consensus estimate of €1.628 by €0.078.
Is Danaher Corp. overvalued?
According to Wall Street analysts Danaher Corp.’s price is currently Undervalued.
Does Danaher Corp. pay dividends?
Danaher Corp. pays a Quarterly dividend of €0.351 which represents an annual dividend yield of 0.63%. See more information on Danaher Corp. dividends here
What is Danaher Corp.’s EPS estimate?
Danaher Corp.’s EPS estimate is 1.68.
How many shares outstanding does Danaher Corp. have?
Danaher Corp. has 702,986,100 shares outstanding.
What happened to Danaher Corp.’s price movement after its last earnings report?
Danaher Corp. reported an EPS of €1.707 in its last earnings report, beating expectations of €1.628. Following the earnings report the stock price went down -14.418%.
Which hedge fund is a major shareholder of Danaher Corp.?
Currently, no hedge funds are holding shares in DE:DAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€195.88 (5.91% Upside)
€195.88 (5.91% Upside)
Blogger Sentiment
Bullish
DE:DAP Sentiment 67%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €11.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.67%
12-Months-Change
Fundamentals
Return on Equity
0.63%
Trailing 12-Months
Asset Growth
13.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Danaher Corp.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
DAP Company Deck
DAP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: revenue and core growth accelerated sequentially (core ex-respiratory +4.5%), EPS grew ~8% and guidance was raised, cash generation was strong (Q2 FCF $1.3B, YTD conversion 124%), and life sciences and diagnostics showed solid performance with several product and M&A catalysts (Masimo closed early and is accretive; StatLab acquisition announced). Key challenges include bioprocessing shipment timing that pushed just over $100M into next year, respiratory-related headwinds (notably in Q3), modest margin pressure (down 20 bps), and continued softness in academic funding. On balance the positive operational execution, cash generation, guidance raise, and strategic M&A/repurchases outweigh the near-term timing and respiratory headwinds.View all DE:DAP earnings summariesDAP Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics
DAP Stock 12 Month Forecast
Average Price Target
€195.88
▲(5.91% Upside)